Adcetris (brentuximab vedotin) has recently become an option for patients dealing with CD30-positive Hodgkin’s lymphoma. Japan is joining a list of more than 70 other countries where this treatment has already been approved.
Seattle Genetics, Inc. has partnered with Takeda Pharmaceutical Company Limited to provide a therapy based on Adcetris in combination with doxorubicin, vinblastine, and dacarbazine (AVD), as a frontline solution for this type of cancer.
“This approval marks another important milestone in expanding the Adcetris brand globally and redefining the way newly diagnosed Hodgkin lymphoma patients are treated around the world,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics in a short press release.
Lymphoma is an umbrella term used to describe over 50 related cancers that originate in the lymphatic system. There are two categories, Hodgkin and non-Hodgkin lymphoma (NHL), each with different characteristics. This treatment is designed for the classical form, distinguishable by the presence of one particular type of cell, known as the Reed-Sternberg cell (CD30). Adcetris binds to this molecule and releases a powerful compound that causes the cancer cells to die.
The decision comes following a Phase 3 ECHELON-1 clinical trial, with more than 1300 participants that tested standard chemotherapy versus a combination of Adcetris and chemo. After a median check-up period of 30 months, it was found that 82.1% of were alive and showing no signs of disease progression, slightly higher than the chemotherapy group. Additionally, patients displayed fewer adverse effects and less lung toxicity.
This new therapy course is hoped to significantly improve the lives of more than 30.000 Hodgkin lymphoma patients around the country.
For more information about Adcetris click here.